NO954880L - Cytidine deaminase - Google Patents

Cytidine deaminase

Info

Publication number
NO954880L
NO954880L NO954880A NO954880A NO954880L NO 954880 L NO954880 L NO 954880L NO 954880 A NO954880 A NO 954880A NO 954880 A NO954880 A NO 954880A NO 954880 L NO954880 L NO 954880L
Authority
NO
Norway
Prior art keywords
cytidine deaminase
cell proliferation
enhancers
blood
stem cells
Prior art date
Application number
NO954880A
Other languages
Norwegian (no)
Other versions
NO954880D0 (en
Inventor
Arne Boeyum
Original Assignee
Nycomed Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Pharma As filed Critical Nycomed Pharma As
Publication of NO954880D0 publication Critical patent/NO954880D0/en
Publication of NO954880L publication Critical patent/NO954880L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04005—Cytidine deaminase (3.5.4.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Denne oppfinnelsen relaterer til cytidin deaminase og dens forsterkere for bruk i celle- proliferasjon, spesielt hematopoese, og bruk av cytidin deaminase inhibitorer for å stimulere celle- proliferasjon, spesielt ved leukemiske forhold og til å mobilisere stamceller i blodet.This invention relates to cytidine deaminase and its enhancers for use in cell proliferation, especially hematopoiesis, and the use of cytidine deaminase inhibitors to stimulate cell proliferation, especially in leukemic conditions and to mobilize stem cells in the blood.

NO954880A 1993-06-01 1995-11-30 Cytidine deaminase NO954880L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939311252A GB9311252D0 (en) 1993-06-01 1993-06-01 Cell growth regualtors
PCT/GB1994/001190 WO1994027632A1 (en) 1993-06-01 1994-06-01 Cell growth regulators

Publications (2)

Publication Number Publication Date
NO954880D0 NO954880D0 (en) 1995-11-30
NO954880L true NO954880L (en) 1996-01-30

Family

ID=10736425

Family Applications (1)

Application Number Title Priority Date Filing Date
NO954880A NO954880L (en) 1993-06-01 1995-11-30 Cytidine deaminase

Country Status (6)

Country Link
EP (1) EP0703787A1 (en)
JP (1) JPH08510385A (en)
AU (1) AU6803694A (en)
GB (1) GB9311252D0 (en)
NO (1) NO954880L (en)
WO (1) WO1994027632A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6410596A (en) * 1995-07-31 1997-02-26 Centre De Recherche De L'hopital Sainte-Justine Cytidine deaminase cdna as a positive selectable marker for ene transfer, gene therapy and protein synthesis
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US8207142B2 (en) 2001-07-31 2012-06-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Inhibitor of DNA methylation
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
JO2778B1 (en) * 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
EP2417146B1 (en) 2009-04-06 2016-07-13 Otsuka Pharmaceutical Co., Ltd. (2'-deoxy-ribofuranosyl)-1,3,4,7-tetrahydro-(1,3)diazepin-2-one derivatives for treating cancer
AU2010234562B2 (en) 2009-04-06 2016-05-12 Otsuka Pharmaceutical Co., Ltd. Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer
JP5730854B2 (en) 2009-04-06 2015-06-10 大塚製薬株式会社 Combination of decitabine and cytidine deaminase inhibitor and its use in the treatment of cancer
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
CA2845585C (en) 2011-08-30 2020-02-18 Astex Pharmaceuticals, Inc. Decitabine derivative formulations
MX2018000016A (en) 2015-07-02 2019-01-31 Otsuka Pharma Co Ltd Lyophilized pharmaceutical compositions.
AU2018310857A1 (en) 2017-08-03 2020-02-13 Otsuka Pharmaceutical Co., Ltd. Drug compound and purification methods thereof

Also Published As

Publication number Publication date
NO954880D0 (en) 1995-11-30
WO1994027632A1 (en) 1994-12-08
EP0703787A1 (en) 1996-04-03
AU6803694A (en) 1994-12-20
GB9311252D0 (en) 1993-07-21
JPH08510385A (en) 1996-11-05

Similar Documents

Publication Publication Date Title
NO954880L (en) Cytidine deaminase
ZA987491B (en) Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
NO985376D0 (en) Quinoline carboxamides as TNF inhibitors and as PDA-IV inhibitors
ZA99550B (en) Potassium channel inhibitors.
ATE250571T1 (en) POTASSIUM CHANNEL BLOCKERS
AU5811001A (en) Cxcr4 antagonist treatment of hematopoietic cells
NO326660B1 (en) Imidazolyl-cyclic acetal compounds, pharmaceutical compositions containing these compounds and use of the compounds
AU9536898A (en) 4-heteroaryl-tetrahydroquinolines and their use as inhibitors of the holesterin-ester transfer protein
CY1107778T1 (en) HUMAN CD45 + ΚΑ / AND FIBROBLAST + MEDITERRANEAN STEM CELLS
NO20001583L (en) Stimulation of hematopoietic cells in vitro
EP0876387A4 (en) Method to improve the biological and antiviral activity of protease inhibitors
BR9408025A (en) Peptidyl compounds and their therapeutic use as metalloproteinase inhibitors
FI844510L (en) ENSYM-RESISTANT IMMUNSYSTEMET MODULERANDE PEPTIDER.
NO871091D0 (en) COMPOSITION DEVICE FOR CATHODIC PROTECTION OF SUBSTRATES IN CONNECTION WITH THIS, AND USE OF THE DEVICE.
IL162836A (en) Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments and pharmaceutical compositions thereof
DE69522109D1 (en) PROTEIN KINASE INHIBITORS C
DE69914357D1 (en) PYRIDIN-4-YL OR PYRIMIDIN-4-YL SUBSTITUTED PYRAZINE
AU7548500A (en) Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents
DK0572688T3 (en) Peptides, with organ-protective activity, method for their preparation and their use in therapy
TR199802649A2 (en) Binding partners for inhibitors of cyclin-dependent kinases.
NO963029L (en) Use of IL-10 to stimulate cytological activity of single-core peripheral blood cells
NO20014537D0 (en) AKT nucleic acids, polypeptides and their use
AU5168099A (en) Use of novel agents inducing cell death in synergy with interferons
EP1527178A4 (en) Novel class ii cytokine receptors and uses thereof
ATE417926T1 (en) COMPOSITIONS FOR MODULATING THE LENGTH OF TELOMERES